Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_3
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution1 total trials
Phase 3Large-scale testing
1(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Completed1
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 31 (100.0%)

Trials by Status

completed133%
not_yet_recruiting133%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_3

Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.

NCT07717450
completed

Visual Outcomes After Extended Depth of Focus Intraocular Lens Implantation With and Without Digital Assistance

NCT06460389
terminated

Study Investigating the Levels and Effects of Low-grade Inflammation in Diabetic Retinopathy of Type 1 Diabetes

NCT00880139

Clinical Trials (3)

Showing 3 of 3 trials
NCT07717450Phase 3

Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.

Not Yet Recruiting
NCT06460389

Visual Outcomes After Extended Depth of Focus Intraocular Lens Implantation With and Without Digital Assistance

Completed
NCT00880139

Study Investigating the Levels and Effects of Low-grade Inflammation in Diabetic Retinopathy of Type 1 Diabetes

Terminated

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3